Pralmorelin
Also known as: GHRP-2, GHRP‑2, Growth Hormone-Releasing Peptide-2, KP-102, Macimorelin precursor analog, Pralmorelin dihydrochloride
Source Pralmorelin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Pralmorelin (also known as GHRP‑2) is a synthetic hexapeptide that stimulates endogenous growth hormone release via activation of the ghrelin receptor. It has been studied for growth hormone deficiency and catabolic conditions but has never received marketing approval.
Mechanism of Action
agonist of the growth hormone secretagogue receptor (GHSR) leading to increased pulsatile growth hormone secretion
Routes of Administration
Goals & Uses
- Anti-aging / GH replacement researchResearchLow
- Muscle mass and body composition improvementPerformance/Body CompositionLow
- Increase endogenous growth hormone secretionEndocrineModerate
- Increase growth hormone secretionEndocrineModerate
- Diagnosis of growth hormone deficiencyDiagnosticHigh
- Appetite stimulationNutritionalLow
- Treat adult growth hormone deficiencyTherapeuticLow
Contraindications
- Hypersensitivity to pralmorelin or excipientsAllergyHigh
- Active malignancyOncologyModerateUse caution or avoid depending on agent and context
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Untreated hypothyroidismEndocrineModerate
Adverse Effects
- EdemaFluid BalanceUncommonSwelling from fluid retention
- HyperglycemiaMetabolicCommonAbnormally high blood glucose
- FlushingVascularCommonWarmth and redness of the skin
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Elevated cortisol/prolactinEndocrineUncommon
- Injection site reactionLocalCommonRedness, swelling, itching, bruising, or pain at the injection site
- Transient hypotensionCardiovascularUncommon
Drug Interactions
- InsulinModerateMay increase risk of low blood sugar
- GlucocorticoidsLow
- Somatostatin analogs (e.g., octreotide)Moderate
- Insulin / Hypoglycemic agentsModerate
Population Constraints
- Pediatric patientsAgeRelative
- Elderly (>75 y)AgeRelative
- Elderly patientsAgeRelative
- Obese individualsMetabolicRelative
- Patients with renal or hepatic impairmentOrgan FunctionRelative
Regulatory Status
- European UnionInvestigationalInvestigational use in clinical trials; no marketing authorization.
- United StatesInvestigationalNever submitted for FDA approval; only used in clinical research.
- United KingdomUnapprovedNot approved by the MHRA; no licensed indication in the UK.
Approved in Japan (Kaken Pharmaceutical) as a diagnostic agent for GH deficiency testing. Not approved by the FDA or EMA for therapeutic or diagnostic use. Widely used in research settings as GHRP-2.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Pralmorelin?
Pralmorelin (also known as GHRP‑2) is a synthetic hexapeptide that stimulates endogenous growth hormone release via activation of the ghrelin receptor. It has been studied for growth hormone deficiency and catabolic conditions but has never received marketing approval.
What is Pralmorelin used for?
Pralmorelin is educationally associated with: Anti-aging / GH replacement research, Muscle mass and body composition improvement, Increase endogenous growth hormone secretion, Increase growth hormone secretion, Diagnosis of growth hormone deficiency, Appetite stimulation, Treat adult growth hormone deficiency. Educational only — not medical advice.
How is Pralmorelin administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Pralmorelin?
Reported adverse effects include: Edema, Hyperglycemia, Flushing, Nausea, Elevated cortisol/prolactin, Injection site reaction, Transient hypotension. This list is not exhaustive — consult a qualified clinician.
Who should avoid Pralmorelin?
Recorded contraindications: Hypersensitivity to pralmorelin or excipients, Active malignancy, Pregnancy, Untreated hypothyroidism. Consult a qualified clinician before use.